EP0000938B1 - Complexes covalents macromoléculaires, procédés de préparation et compositions pharmaceutiques les contenant - Google Patents
Complexes covalents macromoléculaires, procédés de préparation et compositions pharmaceutiques les contenant Download PDFInfo
- Publication number
- EP0000938B1 EP0000938B1 EP78100717A EP78100717A EP0000938B1 EP 0000938 B1 EP0000938 B1 EP 0000938B1 EP 78100717 A EP78100717 A EP 78100717A EP 78100717 A EP78100717 A EP 78100717A EP 0000938 B1 EP0000938 B1 EP 0000938B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- groups
- macromolecule
- amino
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- 229920002521 macromolecule Polymers 0.000 claims description 54
- 125000003277 amino group Chemical group 0.000 claims description 37
- 238000006243 chemical reaction Methods 0.000 claims description 37
- 239000003795 chemical substances by application Substances 0.000 claims description 33
- 125000005843 halogen group Chemical group 0.000 claims description 19
- 239000003053 toxin Substances 0.000 claims description 17
- 231100000765 toxin Toxicity 0.000 claims description 17
- 108700012359 toxins Proteins 0.000 claims description 17
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 16
- -1 amino, carboxyl Chemical group 0.000 claims description 15
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 11
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical class OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 11
- 125000004069 aziridinyl group Chemical group 0.000 claims description 9
- IRKVKAOPPGVMGD-UHFFFAOYSA-N 5-(aziridin-1-yl)-2,4-dinitrobenzoic acid Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(N2CC2)=C1[N+]([O-])=O IRKVKAOPPGVMGD-UHFFFAOYSA-N 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 125000005647 linker group Chemical group 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- 229960004630 chlorambucil Drugs 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- JKJKVYIHGWHFSO-UHFFFAOYSA-N 4-[4-(2-chloroethylamino)phenyl]butanoic acid Chemical compound OC(=O)CCCC1=CC=C(NCCCl)C=C1 JKJKVYIHGWHFSO-UHFFFAOYSA-N 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 5
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 5
- 239000012948 isocyanate Substances 0.000 claims description 5
- 150000002513 isocyanates Chemical class 0.000 claims description 5
- GLBQVJGBPFPMMV-UHFFFAOYSA-N sulfilimine Chemical group S=N GLBQVJGBPFPMMV-UHFFFAOYSA-N 0.000 claims description 5
- 150000004820 halides Chemical class 0.000 claims description 4
- 229910052736 halogen Chemical group 0.000 claims description 4
- 150000002540 isothiocyanates Chemical class 0.000 claims description 4
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 108090001030 Lipoproteins Proteins 0.000 claims description 3
- 102000004895 Lipoproteins Human genes 0.000 claims description 3
- 150000008064 anhydrides Chemical class 0.000 claims description 3
- 230000000781 anti-lymphocytic effect Effects 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 claims 3
- 102000007562 Serum Albumin Human genes 0.000 claims 2
- 108010071390 Serum Albumin Proteins 0.000 claims 2
- 150000001540 azides Chemical class 0.000 claims 2
- HSOGIVQHLAKLSN-UHFFFAOYSA-N 5-azido-2,4-dinitrobenzoic acid Chemical compound OC(=O)C1=CC(N=[N+]=[N-])=C([N+]([O-])=O)C=C1[N+]([O-])=O HSOGIVQHLAKLSN-UHFFFAOYSA-N 0.000 claims 1
- 102000018146 globin Human genes 0.000 claims 1
- 108060003196 globin Proteins 0.000 claims 1
- 239000000243 solution Substances 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 27
- 102000016607 Diphtheria Toxin Human genes 0.000 description 21
- 108010053187 Diphtheria Toxin Proteins 0.000 description 21
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 15
- 229940098773 bovine serum albumin Drugs 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 239000000872 buffer Substances 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000543 intermediate Substances 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 108010044091 Globulins Proteins 0.000 description 7
- 102000006395 Globulins Human genes 0.000 description 7
- 229920005654 Sephadex Polymers 0.000 description 7
- 239000012507 Sephadex™ Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000008878 coupling Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 206010013023 diphtheria Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- NRDQFWXVTPZZAZ-UHFFFAOYSA-N butyl carbonochloridate Chemical compound CCCCOC(Cl)=O NRDQFWXVTPZZAZ-UHFFFAOYSA-N 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000000527 lymphocytic effect Effects 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000005829 chemical entities Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 150000002367 halogens Chemical group 0.000 description 2
- 150000002463 imidates Chemical class 0.000 description 2
- 238000003541 multi-stage reaction Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100000563 toxic property Toxicity 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- AENZGWONVTXLRC-UHFFFAOYSA-N 2-(2,5-dioxopyrrol-1-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1N1C(=O)C=CC1=O AENZGWONVTXLRC-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical group CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- JDFXJJLFADUZIY-UHFFFAOYSA-N CON(C(CC1)=O)C1=O Chemical compound CON(C(CC1)=O)C1=O JDFXJJLFADUZIY-UHFFFAOYSA-N 0.000 description 1
- RZXMPPFPUUCRFN-UHFFFAOYSA-N Cc(cc1)ccc1N Chemical compound Cc(cc1)ccc1N RZXMPPFPUUCRFN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 125000004018 acid anhydride group Chemical group 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical group 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- ZBKFYXZXZJPWNQ-UHFFFAOYSA-N isothiocyanate group Chemical group [N-]=C=S ZBKFYXZXZJPWNQ-UHFFFAOYSA-N 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/06—Enzymes or microbial cells immobilised on or in an organic carrier attached to the carrier via a bridging agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
Definitions
- the present invention relates to macromolecular covalent conjugates, methods for their preparation and pharmaceutical compositions containing them. More specifically, the method for making said conjugates involves linking two macromolecules through a linking agent having two or more active groups of different reactivity.
- enzymes may be linked to water-insoluble carriers and thereby insolubilised; drugs may be linked to carrier proteins (e.g. specific antibodies) to enable them to be localised at the site where the drug is required; or carrier proteins may be linked to liposomes containing entrapped drugs and derived from phospholipids having a reactive end group, again permitting localisation of drugs at specific sites.
- carrier proteins e.g. specific antibodies
- the French Patent 23 34 954 discloses a reagent for enzymatic immunologic determinations comprising an ester of maleimidobenzoic acid and N-hydroxysuccinimide, which can be used for linking macromolecules, i.e. enzymes and antigens.
- a common method of linking macromolecules comprises the reaction, in a single step of the two macromolecules and the linking agent.
- dimers or polymers of the macromolecules used are formed as well as the desired adduct. This dimerisation or polymerisation is disadvantageous because:-
- the steps may be expressed as: in which M 1 , M 2 , A, B and L are as defined above and L' may be the same as L or a modified version of L (derived from A and L) and L" may be the same as L' or a modified version of L' (derived from L' and B).
- L is used solely but should be considered to include the possibilities of L' and L" as the context requires.
- Linking agents suitable for use in the present invention include those in which the first group, A, will undergo reaction at a temperature, pH or level of irradiation at which the second group, B, is not reactive.
- Reactive groups used as group A (the more reactive group) in such linking agents are (a) activated carboxyl groups, for example those of formula -COX in which X is a halogen atom, e.g. chlorine or bromine, (to give acid halides); an azido group -N 3 ; the residue of an organic acid, e.g. CH3C02- or (to give acid anhydrides) or the residue of an alcohol e.g. (to give activated esters) which will react with amino functions of macromolecules to give amide links;
- activated carboxyl groups for example those of formula -COX in which X is a halogen atom, e.g. chlorine or bromine, (to give acid halides); an azido group -N 3 ; the residue of an organic acid, e.g. CH3C02- or (to give acid anhydrides) or the residue of an alcohol e.g. (to give activated esters) which will react with amino functions of macromolecules
- Suitable reactive groups B are activated halogen groups i,e, halogen groups two carbon atoms removed from a heteroatom carrying a lone pair of electrons (electron releasing group) for example halogen groups in radicals such as -S-CH 2 CH 2 -Cl or (mustards) (which are unreactive at the lower temperatures at which the aforementioned activated carboxyl groups may be made to react) or halogen atoms in an a-position relative to a carbonyl group e.g.
- a-halocarboxylic acids in a-halocarboxylic acids; the heterocyclic aziridine ring which is stable at neutral or alkaline pH but which undergoes ring opening at acid pH; and an arylazido group which becomes reactive on irradiation with light.
- Linking agents which are preferably used in the method of the invention are: acyl derivatives of chlorambucil (4-[p-bis(2-chloroethyl)aminophenyl]butyric acid), e.g. and of 4-[p-(2-chloroethyl)aminophenyl]butyric acid, e.g. the acyl groups of which will undergo reaction with primary or secondary amino groups at less than 10°C, preferably less than 5°C, and the chloroethyl amino groups of which will react with amino or carboxyl groups at 25 to 30°C.
- the chloroethylamino groups react preferentially with amino groups in the macromolecule M 2 and as the pH is lowered the amount of such reaction with amino groups decreases, i.e. the reaction with carboxyl groups becomes relatively more important.
- a further way of increasing the difference in reactivities between the A and B groups when the B group is a halogen group two carbon atoms removed from a heteroatom carrying a lone pair of electrons, is to carry out the A-group reaction in the presence of a high concentration, e.g. greater than 1 molar, of halide, e.g. chloride, ions as this reduces further the reactivity of the B group.
- the reaction should preferably be carried out in the presence of a lower concentration of the halide ions, the halide ion concentration being reduced between steps, e.g. by ultrafiltration.
- This halide ion concentration adjustment is particularly suitable for the present class of linking agents.
- linking agents include acyl derivatives of 2,4-dinitro-5-aziridinyl-benzoic acid, for example the mixed anhydride: in which the acid anhydride group will react at alkaline or neutral pH with primary or secondary amino groups on the macromolecule M 1 to give amide links, with the aziridine ring being opened at acid pH by carboxyl groups on the macromolecule M 2 ; and acyl derivatives of 5-azido-2,4-dinitrobenzoic acid, e.g. in which the acid chloride group reacts with amino groups under conditions of low radiation intensity e.g. in a dark room, the azide group then reacting, after elimination of a molecule of nitrogen, by insertion into a C-H bond when irradiated with visible light of a suitable higher intensity.
- the mixed anhydride in which the acid anhydride group will react at alkaline or neutral pH with primary or secondary amino groups on the macromolecule M 1 to give amide links, with the aziridine ring being opened at acid pH by carb
- the linking group L of the linking agent serves as a carrier for the two reactive groups A and B and may be any group which serves such a purpose, provided that the differential activity between the groups A and B (as herein defined) is retained.
- the linking agent portion L may advantageously contribute to the differential reactivity of groups A and B.
- the group L used will generally be dicated by the availability or ease of synthesis of the linking agent A-L-B and conveniently the two groups A and B are attached to an aromatic ring or rings, preferably a benzene ring.
- the linking agent contains only one of the more reactive groups A in order to prevent dimer or polymer formation in the first step of the reaction. It is further preferable that only one group B is present in the linking agent, although the use of linking agents having two or more of such groups is not precluded.
- stepwise reaction it is preferred to isolate and purify (for example by chromatography) the product of the first step before the second linking reaction is performed, to remove unreacted linking agent and, if desired, any unreacted macromolecule or any byproduct, the presence of which is undesirable. It will in general also be necessary to purify the final product to remove any unreacted starting materials or undesirable side product.
- the products obtained by the method of the invention will not consist of a single chemical entity but will comprise a series of conjugates falling within a molecular weight band, by which they may be characterised.
- the degree of variation will depend upon the number and variety of functional groups in the macromolecules M 1 and M 2 .
- the products obtained by the method of the present invention have a ratio of 1:1 with respect to the two macromolecules M 1 and M 2 .
- the intermediate covalent conjugate obtained is of the form M 1 ⁇ (L ⁇ B) n , where n is greater than 1, and thus the intermediate covalent conjugate itself will not be a single chemical entity but a series of conjugates comprising macromolecules having a varying number of linking groups attached thereto. It is advisable to produce intermediate conjugates of this type as in the second step not all of the groups B in the linking molecules will react with the second macromolecule M 2 because of side reactions, for example with the solvent or with other components in the reaction mixture.
- reaction techniques known in the art for controlling undesirable side reactions e.g. using an excess of one component or by adding a component to the reaction mixture continuously during the course of the reaction, may be employed to try to obtain the desired ratio.
- Any macromolecules containing suitable functional groups may be linked by using linking agents containing the afore-mentioned groups, although the method is particularly applicable to macromolecules of biological origin, such as peptides e.g. proteins, especially antigens, antibodies, enzymes, lipoproteins, serum albumins, toxins and toxoids.
- peptides e.g. proteins, especially antigens, antibodies, enzymes, lipoproteins, serum albumins, toxins and toxoids.
- the macromolecule M 1 reacts via its amino groups
- macromolecule M 2 reacts via its amino or carboxyl groups, or C-H bonds.
- the method of the present invention is particularly useful for linking together a chemotherapeutic agent, e.g. diphtheria toxin, to an antibody, i.e. immunoglobulin, since the complex so produced is thereby rendered site specific and the chemotherapeutic agent may be concentrated at the required. point, thereby reducing the dose required and hence side-effects whilst at the same time improving the therapeutic effect of the therapeutic agent.
- a chemotherapeutic agent e.g. diphtheria toxin
- an antibody i.e. immunoglobulin
- covalent conjugates of the present invention may be used for a variety of purposes.
- anti-cancer agents of improved selectivity for treatment of the disease in a mammal, including man may be obtained by linking a tumour-specific antibody to the original anti-cancer agent.
- Improved immunosuppressive agents for treatment or prophylaxis in a mammal, including man of for example, graft versus host (GVH) disease or transplant (graft) rejection by a host mammal and autoimmune diseases may be obtained, for example, by linking one or more toxins to an anti-lymphocytic globulin.
- anti-parasitic agents for treatment or prophylaxis of diseases in a mammal, including man, caused by parasites may be obtained by linking an antibody for the parasite e.g. Trypanosoma cruzi, to a toxin, e.g. diphtheria toxin.
- a toxin e.g. diphtheria toxin.
- the covalent conjugates of the present invention may be used as reagents in enzyme linked immunosorbent assay (E.L.i.S.A) reactions.
- E.L.i.S.A enzyme linked immunosorbent assay
- an antibody to the substance being detected is labelled by being linked to an enzyme suitable for catalysing a readily monitored reaction.
- the conjugates obtained by the present process generally have greater activity than complexes produced by earlier methods.
- a suitable dose for a mammal of a covalent conjugate of the invention will lie in the range of 10- 6 to 10 molar equivalents of the amount of the particular chemotherapeutic agent in the conjugate which would be required in its unbound form for the therapeutic effect obtained.
- the carrier used in a pharmaceutical formulation may be any that is acceptable, i.e. does not have any substantially deleterious effect on the recipient.
- the carrier used for a particular administration will depend upon the route used, which would usually be parenteral; for example a liquid, e.g. aqueous, carrier would be suitable for parenteral administration, e.g. intravenous injection.
- a suitable aqueous carrier is water for injections.
- formulations of the present invention in liquid media may be freeze-dried for convenient storage.
- Chlorambucil 25 ml was dissolved in solution (B) (1.0 ml) and to an aliquot (0.3 ml) of the solution obtained was added solution (A) (0.3 ml). The reaction mixture was then stirred in an ice bath for 30 minutes.
- the reaction mixture was added to a solution of horse anti-human lymphocytic globulin (ALG; 50 mg) in a mixture of saline borate (SB) buffer (0.05 M borate buffer containing 1.7% sodium chloride, fungicidal and bacteriostatic agents; pH 8.9-9.1) (5 ml) and dioxan (1.4 ml) and stirred at 4°C for 90 minutes to form a conjugate.
- SB saline borate
- the protein band (detected on an LBK flowthrough Spectrophotometric cell at 281 nm) (20 ml) was collected and concentrated to 2.5 ml in an Amicon ultrafiltration cell. A sample (0.1 ml) of the concentrate was diluted for spectrophotometric estimation of the level of binding of chlorambucil to the ALG (all done in a cold room at 4°C).
- the concentrated conjugate solution (1 ml) was added to diphtheria toxin (1.05 ml) (25 mg/ml + 0.05 ml of 1 125- radio-labelled toxin) and stirred at room temperature for 30 hours.
- the high molecular weight fraction having M.wt. of 180,000 to 250,000 comprised a series of conjugates of ALG and diphtheria toxin conjugated through chlorambucil, there being an average of from 1.0 to 1.5 moles of diphtheria toxin conjugated, through a chlorambucil residue, to each mole of ALG.
- a second high molecular weight fraction (M. wt >250,000) was also obtained.
- the fluorescent titre for ALG-chlorambucildiphtheria toxin (M.wt 180,000 to 250,000) 1:1 was 3.0 x 10- 5 mM which is insignificantly different from the titre for ALG alone (2.6 x 10- 5 mM).
- the linkage of diphtheria toxin to ALG did not affect the antigen binding capacity of the antibody.
- the conjugate of M.wt > 250,000 did show a somewhat reduced binding capacity, with a titre of 6.6 x 10- 5 mM.
- ALG-chlorambucil-diphtheria toxin (M.wt 180,000 to 250,000) was as toxic to the macrophages as was diphtheria toxin alone, killing down to 10 -12 M, or about 50 molecules per cell.
- the conjugate of higher M.wt. ( > 250,000) did however show a twenty-fold reduction in its capacity to kill macrophages compared to diphtheria toxin.
- CLA 4 cells (2 x 10 5 cells per 200 1 culture) in Hanks balanced salt solution containing 10% foetal calf serum were exposed to diphtheria toxin for 1 hour before washing five times. Cell survival was measured at the end of the 24 hours incubation by the ability of the cells to incorporate 3 H-leucine into protein.
- diphtheria toxin was not very effective at killing CLA 4 cells compared with other sensitive cells such as guinea pig macrophages and human fibroplasts.
- diphtheria toxin would only kill CLA 4 cells at concentrations down to 10- 9 M, and on short exposure no cell death was apparent even at the maximum concentration used of 10 -8 M.
- the ALG-chlorambucil-diphtheria toxin conjugate (M.W. 180,000 to 250,000) was very potent and killed CLA 4 cells at concentrations down to 10-"M for both 1 hour and 24-hour exposures.
- diphtheria toxin By linking diphtheria toxin to ALG its cytotoxic effect on 1 hour exposure to CLA 4 cells was improved by a factor of about 1000. ALG alone did not kill CLA 4 cells, and did not modify the toxicity of diphtheria toxin when presented simultaneously to the cells.
- diphtheria toxin when diphtheria toxin was coupled to a non-immune immunoglobulin which had no ability to bind to CLA, cells the conjugate was 50 fold less toxic than diphtheria toxin alone so that the improved toxicity of ALG-chlorambucil-diphtheria toxin seems to be specific for the target cell. This is supported by the finding that ALG-chlorambucil-diphtheria toxin was about twenty-fold less efficient at killing human fibroblasts, a cell to which ALG does not bind, than was diphtheria toxin alone.
- HyG human y globulin
- BSA bovine serum albumin
- BSA bovine serum albumin
- the protein band (detected as described in Example 1) (in 13 ml of eluant) was collected and a sample was diluted for spectrophotometric determination of the level of binding of 2-4-dinitro-5- aziridinyl benzoic acid to the BSA.
- the protein band (conjugate) was concentrated to 2.0 ml in an Amicon ultra-filtration cell and the concentrate so obtained was added to HyG (50 mg) in SB buffer (2 ml). The pH at this point was 9.1.
- reaction mixture was stirred rapidly while the pH was adjusted to 5.3 by slow addition of 1 N hydrochloric acid from a microsyringe.
- hydrochloric acid was complete the reaction mixture was stirred in a water bath at 40°C and the reaction followed spectrophotometrically, small samples being taken every 5 hours, diluted and examined by UV spectroscopy. After 20 hours a shift of Amax from 336 nm to 356 nm indicated that the reaction was complete and the pH was adjusted to 9.1 by slow addition, to the rapidly stirred mixture, of 1N sodium hydroxide.
- the high molecular weight fraction (M.wt >150,000) comprised a series of conjugates of bovine serum albumin and human (HyG) having an average of 9 moles of 2,4-dinitro-5-aziridinyl benzoic acid bound to each mole of BSA and to which conjugates was bound 80% of the labelled BSA. It was estimated that the conjugate band contained 1 to 2 molecules of BSA for each molecule of HyG.
- reaction mixture was allowed to cool and applied to a dry silica gel column which was washed with chloroform (200 ml) to elute 2 minor bands.
- the solvent was then changed to chloroform:methanol:water (70:30:5), and the product first being adsorbed on to the top of the column and then eluted as two major bands; when the second band started to elute the solvent was changed to pure ethanol and all the material was eluted from the column.
- the conjugate band (the first major band eluted) was dried by evaporation under reduced pressure at less than 40°C, redissolved in chloroform (20 ml), filtered through a Millipore (registered Trade Mark) filter (0.22,um pore size) to remove silica fines and dried by rotary evaporation (reduced pressure and ambient temperature).
- a yellow liquid residue (presumed to be largely water) remained and was removed by successive addition and evaporation under reduced pressure of dry benzene.
- the product travels as a single sopt (Rf. 0.6) in the above mentioned TLC systems.
- Liposomes are prepared from egg lecithin (10 mg) and dipalmitoyl phosphatidyl ethanolamine (2 mg) (obtained as described above) by the following method.
- the lipids are mixed and dried as a thin film under reduced pressure on a rotary evaporator at ambient temperature and then suspended in sodium chloride (1 ml, 73 ml) and phosphate buffer (1 mM; pH 7.0); (at this pH the aziridine ring of the 2,4-dinitro-5-aziridinyl benzoic acid residue is poorly reactive).
- a solution (2 ml; 15 mg/ml) of bovine serum albumin (BSA) in sodium chloride (73 mM) and acetate buffer (5 mM) is then added and the pH of the mixture is adjusted to 4.1 with aqueous hydrochloric acid.
- BSA bovine serum albumin
- acetate buffer 5 mM
- BSA binds electrostatically to the liposomes (the liposomes are negatively charged, the BSA is not positively charged), and the 2,4-dinitro-5-aziridinyl benzoic acid residue reacts with suitable residues on the liposome.
- the pH is adjusted to 7.0 with aqueous sodium hydroxide and the liposomes are separated from unbound BSA by gel cchromato- graphy on Sepharose 6B.
- Chlorambucil (7.5 mg) was dissolved in 0.3 ml solution (B) and to the stirred, cooled (2°C) solution was added 0.3 ml solution (A). After 30 minutes a pre-cooled solution of protein-1 (5 ml 10 mg protein-1 per ml in borate:NaCI (0.05 M:1.7%, pH 9) and dioxan (1.4 ml) was added quickly and stirring continued at 2°C for 1 t to 2 hours. The solution was then passed through a jacketed (2°C) column of Sephadex SG 25 and eluted with the same borate-saline buffer.
- the protein containing eluate (20 ml)-detected with an LKB flow-through spectrophotometric cell at 280 nm- was run into a solution of protein-2 (1 ml 25 mg protein-2 per ml in the same borate-saline buffer).
- a small quantity of radio-iodine labelled (1 125 ) protein-2 was present to assist quantitation of the results.
- Fractions were collected and the molecular weights were calculated from the elution volumes.
- the protein-2 content of the fractions was estimated from the gamma-radiation counts and the protein-1 content from the U.V. absorbance at 280 nm after deducting the contribution from protein-2.
- fractions containing unconjugated protein-1 and protein-2 fractions of M.wt 180,000 to 250,000 and >250,000 were obtained.
- the fraction of M.wt 180,000 to 250,000 consisted of conjugates of protein-1 and protein-2, there being an average of 1 to 1.5 molecules of protein-2 coupled to each molecule of protein-1.
- protein-1 it is possible to use normal horse and normal bovine immunoglobulin, horse antimouse thymocytic globulin, horse anti-human lymphocytic globulin and F(ab) 2 fragments (obtained by pepsin digestion) of normal horse immunoglobulin and of horse anti-human lymphocytic globulin.
- protein-2 it is possible to use bovine serum albumin, diphtheria toxin and abrin.
- Sephadex SG 150 superfine for the final chromatographic separation and in this case the fraction of M.wt 130,000 to 200,000 contained predominantly a 1:1 protein-1 :protein-2conjugate.
- a portion of each of the covalent conjugates formed in Examples 1 to 13 is dispersed into separate aliquots of water for injections so as to form respective solutions suitable for injection.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
- Polyurethanes Or Polyureas (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (19)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB3517377 | 1977-08-22 | ||
GB3517377 | 1977-08-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0000938A1 EP0000938A1 (fr) | 1979-03-07 |
EP0000938B1 true EP0000938B1 (fr) | 1984-10-17 |
Family
ID=10374687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP78100717A Expired EP0000938B1 (fr) | 1977-08-22 | 1978-08-21 | Complexes covalents macromoléculaires, procédés de préparation et compositions pharmaceutiques les contenant |
Country Status (5)
Country | Link |
---|---|
US (1) | US4275000A (fr) |
EP (1) | EP0000938B1 (fr) |
JP (1) | JPS5470384A (fr) |
DE (1) | DE2862449D1 (fr) |
IT (1) | IT1107772B (fr) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4315851A (en) * | 1978-12-29 | 1982-02-16 | Kureha Kagaku Kogyo Kabushiki Kaisha | Pharmaceutical composition having antitumor activity |
JPS55136235A (en) * | 1979-04-09 | 1980-10-23 | Teijin Ltd | Antitumor protein complex and its preparation |
JPS5686121A (en) * | 1979-12-14 | 1981-07-13 | Teijin Ltd | Antitumor proten complex and its preparation |
EP0044167A3 (fr) * | 1980-07-14 | 1982-04-21 | The Regents Of The University Of California | Agent cytotoxique dirigé par un anticorps |
JPS57106625A (en) * | 1980-12-22 | 1982-07-02 | Teijin Ltd | Cytotoxic protein complex and its preparation |
JPS57106626A (en) * | 1980-12-22 | 1982-07-02 | Teijin Ltd | Cytotoxic protein complex and its preparation |
FI820020L (fi) * | 1981-01-12 | 1982-07-13 | Lilly Industries Ltd | Immunoglobulinkonjugater |
US5144011A (en) * | 1981-06-26 | 1992-09-01 | Boston University | Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers |
US4631190A (en) * | 1981-06-26 | 1986-12-23 | Shen Wei C | Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers |
FR2523311B1 (fr) * | 1982-03-12 | 1985-12-27 | Pasteur Institut | Produit de couplage entre une albumine et un ligand specifique, obtention et applications dans le domaine biologique |
ATE25197T1 (de) * | 1982-05-12 | 1987-02-15 | Harvard College | Hybridproteinekodierende fusionierte gene, sie enthaltende klonierungsvektoren und deren verwendung. |
US4486344A (en) * | 1983-03-28 | 1984-12-04 | Miles Laboratories, Inc. | Urea-linked immunogens, antibodies, and preparative method |
GB8334499D0 (en) * | 1983-12-24 | 1984-02-01 | Beecham Group Plc | Derivatives |
GB8400653D0 (en) * | 1984-01-11 | 1984-02-15 | Beecham Group Plc | Conjugates |
FR2562671B1 (fr) * | 1984-04-10 | 1986-07-25 | Immunotech Sa | Procede pour le dosage immunologique des monoamines |
US4666884A (en) * | 1984-04-10 | 1987-05-19 | New England Deaconess Hospital | Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls |
US4695624A (en) * | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
US4681760A (en) * | 1985-04-17 | 1987-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method of conferring immunotolerance to a specific antigen |
EP0238645A1 (fr) * | 1985-10-03 | 1987-09-30 | Biotechnology Research Partners, Ltd. | Nouveaux systemes d'administration de medicaments a base de lipoproteines |
NZ217844A (en) * | 1985-10-11 | 1989-10-27 | Sumitomo Pharma | A sustained release pharmaceutical composition containing silicone elastomer and an albumin |
JP2514950B2 (ja) * | 1986-03-10 | 1996-07-10 | エフ・ホフマン―ラ ロシユ アーゲー | 化学修飾蛋白質,その製造法および中間体 |
JPH0690206B2 (ja) * | 1986-06-16 | 1994-11-14 | 日本赤十字社 | 抗原抗体複合物及びその使用方法 |
US4916118A (en) * | 1986-08-18 | 1990-04-10 | Board Of Regents, The University Of Texas System | Pharmaceutical administration systems containing chemotactic peptides |
US4835258A (en) * | 1986-12-24 | 1989-05-30 | Northwestsern University | Conjugation of aromatic amines or nitro-containing compounds with proteins or polypeptides by photoirradiation of the azide derivatives with ultraviolet light in order to produce antibodies against the haptens |
CA1335721C (fr) * | 1987-12-24 | 1995-05-30 | Patrick E. Guire | Biomolecule fixee a une surface solide a l'aide d'un espaceur et methodes de fixation |
US5057301A (en) * | 1988-04-06 | 1991-10-15 | Neorx Corporation | Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents |
US5219564A (en) * | 1990-07-06 | 1993-06-15 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
CA2048078A1 (fr) * | 1990-11-15 | 1992-05-16 | Wolfgang A. Wrasidlo | Modification chimique des anticorps pour la creation d'immunoconjugues |
US5595732A (en) * | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
US5965566A (en) * | 1993-10-20 | 1999-10-12 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5880131A (en) * | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5622986A (en) * | 1993-10-20 | 1997-04-22 | Enzon, Inc. | 2'-and/or 7-substituted taxanes |
US5919455A (en) * | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5643575A (en) * | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5951974A (en) * | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
NZ276943A (en) * | 1993-11-10 | 1998-02-26 | Schering Corp Substituted For | Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation |
RU2058553C1 (ru) * | 1994-03-18 | 1996-04-20 | Иван Николаевич Головистиков | Способ определения супрессорного звена иммунного статуса человека |
RU2056852C1 (ru) * | 1994-03-18 | 1996-03-27 | Иван Николаевич Головистиков | Средство для лечения аутоиммунных заболеваний с иммунодефицитом супрессоров и способ лечения аутоиммунных заболеваний |
US5730990A (en) * | 1994-06-24 | 1998-03-24 | Enzon, Inc. | Non-antigenic amine derived polymers and polymer conjugates |
US5738846A (en) * | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
US6309646B1 (en) | 1996-05-09 | 2001-10-30 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine | Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates |
US9249240B2 (en) * | 2007-12-20 | 2016-02-02 | Basf Se | Graft polymers having oligoalkylenimine side chains, process for their preparation and their use |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1908290C3 (de) * | 1969-02-19 | 1982-04-08 | Boehringer Mannheim Gmbh, 6800 Mannheim | Acrylamid-mischpolymerisat |
US3843447A (en) * | 1972-09-22 | 1974-10-22 | Syva Co | Photolytically activated coupling to polypeptides |
CA1023287A (fr) * | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Procede de fixation d'une proteine sur un substrat |
US4081329A (en) * | 1972-12-08 | 1978-03-28 | Boehringer Mannheim Gmbh | Preparation of carrier-bound macromolecular compounds |
DE2461439C3 (de) * | 1974-12-24 | 1980-03-20 | Behringwerke Ag, 3550 Marburg | Verfahren zur Herstellung eines schützenden Antigens von Bordetella Pertussis sowie jenes enthaltendes Mittel |
CH594696A5 (fr) * | 1975-03-18 | 1978-01-31 | Battelle Memorial Institute | |
US4007089A (en) * | 1975-04-30 | 1977-02-08 | Nelson Research & Development Company | Method for binding biologically active compounds |
IL47468A (en) * | 1975-06-12 | 1979-05-31 | Rehovot Res Prod | Process for the cross-linking of proteins using water soluble cross-linking agents |
DE2537129C3 (de) * | 1975-08-20 | 1978-05-03 | Boehringer Mannheim Gmbh, 6800 Mannheim | Reaktive unsymmetrische, einen Digoxin- bzw. Digitoxinrest enthaltende Dicarbonsäureester, Verfahren zu deren Herstellung sowie ihre Verwendung zur Herstellung von Testreagentien |
US4096138A (en) * | 1975-12-08 | 1978-06-20 | Scherr George H | Immunological test procedure |
JPS5272284A (en) * | 1975-12-12 | 1977-06-16 | Dainippon Pharmaceutical Co | Enzymeeimmunoassay reagent |
US4098645A (en) * | 1976-02-24 | 1978-07-04 | W. R. Grace & Co. | Immobilization of proteins with polyurethane polymers |
US4172072A (en) * | 1977-10-20 | 1979-10-23 | Ashmead H H | Buffered enzymatically produced metal proteinates |
-
1978
- 1978-08-21 US US05/934,710 patent/US4275000A/en not_active Expired - Lifetime
- 1978-08-21 IT IT50797/78A patent/IT1107772B/it active
- 1978-08-21 DE DE7878100717T patent/DE2862449D1/de not_active Expired
- 1978-08-21 EP EP78100717A patent/EP0000938B1/fr not_active Expired
- 1978-08-21 JP JP10170778A patent/JPS5470384A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP0000938A1 (fr) | 1979-03-07 |
IT1107772B (it) | 1985-11-25 |
IT7850797A0 (it) | 1978-08-21 |
US4275000A (en) | 1981-06-23 |
DE2862449D1 (en) | 1984-11-22 |
JPS5470384A (en) | 1979-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0000938B1 (fr) | Complexes covalents macromoléculaires, procédés de préparation et compositions pharmaceutiques les contenant | |
US4868109A (en) | Immunological antibody complex, its preparation and its use | |
US4340535A (en) | Cytotoxic products formed by covalent bonding of the A chain of ricin with an antibody and the process for their preparation and use | |
JPS624368B2 (fr) | ||
EP0031999A2 (fr) | Protéine hybride antitumeur et procédé pour sa préparation | |
JPH04334377A (ja) | 酸−不安定性リンカー分子 | |
JPH01146891A (ja) | モノホスホリルリピドaの誘導体 | |
US4543211A (en) | Conjugate having cytotoxicity and process for the preparation thereof | |
EP0217577A2 (fr) | Complexes d'anticorps d'agents diagnostiques ou thérapeutiques modifiés par un haptène | |
EP0518930A1 (fr) | Compositions a base de cyclodextrines | |
US4594336A (en) | Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for obtaining and its application | |
Ryan et al. | Localization of angiotensin converting enzyme (kininase II). I. Preparation of antibody-heme-octapeptide conjugates | |
AU662627B2 (en) | Novel compounds and conjugates | |
EP0312360B1 (fr) | Dérivés de 25-hydroxy vitamine D3 | |
US6262265B1 (en) | Non-hydrolyzable analogs of heroin metabolites suitable for use in immunoassay | |
Ghitescu et al. | Protein AG-gold complex: An alternative probe in immunocytochemistry. | |
JPS6084297A (ja) | 新規なアミノプリン誘導体 | |
US4954637A (en) | Certain maleimide-N-alkylenecarboxylate-ortho-nitrobenzenesulfonic acid esters and derivatives useful for coupling biological materials | |
US5144009A (en) | Conjugates in which a monovalent carboxylic ionophore is associated by means of a covalent bond with a macromolecule, their use as immunotoxin potentiators and the intermediate activated inophores | |
US4943636A (en) | Certain pyridyl-di-sulfide-alkylenecarbonxylate-ortho-nitro-phenylsulfonic acid esters useful for coupling biological materials | |
CA1086306A (fr) | Reactif pour epreuve d'immunofluorescence et procede de preparation | |
Linford et al. | Comparisons of the chemical and biologic properties of triaziquone and triaziquone-protein conjugates | |
CA2121990A1 (fr) | Conjugues anticorps-medicament | |
SU800877A1 (ru) | Способ получени конъюгированногоС бЕлКОМ АМиНАзиНА | |
EP0221505A2 (fr) | Méthode de préparation d'immunoglobulines convenant à l'administration intraveineuse |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): CH DE FR GB SE |
|
17P | Request for examination filed | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: NATIONAL RESEARCH DEVELOPMENT CORPORATION |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Designated state(s): CH DE FR GB SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY Effective date: 19841017 Ref country code: CH Effective date: 19841017 Ref country code: SE Effective date: 19841017 |
|
REF | Corresponds to: |
Ref document number: 2862449 Country of ref document: DE Date of ref document: 19841122 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
EN | Fr: translation not filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19860501 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 19910719 Year of fee payment: 14 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Effective date: 19920821 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 19920821 |